

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

RD-ES

RRID:CVCL_2169

Type: Cell Line

Proper Citation

RRID:CVCL_2169

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2169

Proper Citation: RRID:CVCL_2169

Description: Cell line RD-ES is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Ewing sarcoma

Defining Citation: [PMID:8040301](#), [PMID:8221663](#), [PMID:8378080](#), [PMID:9738976](#), [PMID:11423975](#), [PMID:18082704](#), [PMID:18160777](#), [PMID:19787792](#), [PMID:20215515](#), [PMID:21822310](#), [PMID:22142829](#), [PMID:22460905](#), [PMID:25010205](#), [PMID:25223734](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:26428435](#), [PMID:28196595](#), [PMID:29464090](#), [PMID:30879952](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:36476851](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RD-ES

Synonyms: RDES, RDES-1

Cross References: BTO:BTO_0004202, CLO:CLO_0008774, EFO:EFO_0002316, CLDB:cl4128, CLDB:cl4129, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ATCC:HTB-166, BCRJ:0267, BioGRID_ORCS_Cell_line:194, BioSample:SAMN03470929, BioSample:SAMN10987904, cancercellines:CVCL_2169, Cell_Model_Passport:SIDM01316, CLS:300410, Cosmic:759890, Cosmic:1078386,

Cosmic:1082506, Cosmic:1085906, Cosmic:1381107, Cosmic:1718429, Cosmic:2228230, Cosmic:2250477, Cosmic:2294586, DepMap:ACH-000041, DSMZ:ACC-260, DSMZCellDive:ACC-260, GDSC:1330996, GEO:GSM393042, GEO:GSM510006, GEO:GSM887527, GEO:GSM888609, GEO:GSM1676310, GEO:GSM1701644, GEO:GSM5359730, GEO:GSM5359731, GEO:GSM5359732, GEO:GSM5359733, GEO:GSM5359734, GEO:GSM5359735, GEO:GSM5362971, GEO:GSM5362972, GEO:GSM5362973, GEO:GSM5362974, GEO:GSM5362975, GEO:GSM5362976, GEO:GSM5363991, GEO:GSM5363992, GEO:GSM5363993, GEO:GSM5363994, GEO:GSM5363995, IARC_TP53:1272, IARC_TP53:8400, IGRhCellID:RDES, LiGeA:CCLE_906, LINCS_LDP:LCL-1455, PharmacoDB:RDES_1297_2019, Progenetix:CVCL_2169, Wikidata:Q54949536

ID: CVCL_2169

Record Creation Time: 20220427T221454+0000

Record Last Update: 20260815T235624+0000

Ratings and Alerts

No rating or validation information has been found for RD-ES.

No alerts have been found for RD-ES.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. *Cancer research*, 86(11), 2660.

Manara MC, et al. (2024) Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages. *Cancer immunology research*, 12(2), 247.

Mancarella C, et al. (2023) Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. *Cancer gene therapy*, 30(9), 1285.

Golinelli G, et al. (2022) Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma. *Translational oncology*, 15(1), 101240.

Martin JC, et al. (2022) WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe.

Cancer research communications, 2(6), 471.

Palve V, et al. (2022) The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell chemical biology, 29(2), 202.

Orth MF, et al. (2022) Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. Cell reports, 41(10), 111761.

Dirks WG, et al. (2021) Cross-contamination meets misclassification: Awakening of CHP-100 from sleeping beauty sleep-A reviewed model for Ewing's sarcoma. International journal of cancer.

Mercatelli N, et al. (2020) Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC. Cancer letters, 469, 111.

Yeung C, et al. (2019) Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. Cancer research, 79(19), 5060.

Srivastava S, et al. (2019) ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell reports, 29(1), 104.